- Home
- WGRX vs BCTX Comparison
WGRX vs BCTX Comparison
Compare WGRX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGRX | BCTX |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 28.8M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | WGRX | BCTX |
|---|---|---|
| Price | $0.09 | $4.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 5.5M | 133.6K |
| Earning Date | 05-21-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.61 |
| 52 Week High | $3.00 | $14.68 |
Technical Indicators
Market Signals| Indicator | WGRX | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 51.45 |
| Support Level | $0.10 | $4.10 |
| Resistance Level | $0.17 | $4.63 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 38.16 | 79.17 |
Price Performance
Historical ComparisonAbout WGRX Wellgistics Health Inc.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.